Divi’s Laboratories Q1 FY27 Call Set for Aug 1, 2026

Earnings call scheduled for August 1

Divi's Laboratories Limited has scheduled an earnings conference call for August 01, 2026, starting at 14:00 IST. The call is planned to review the company’s performance for the quarter ended June 30, 2026, which corresponds to Q1 FY27.

The company said the discussion will follow the release of its quarterly numbers. For investors tracking quarterly operating trends and management commentary, the timing is relevant because it places the financial disclosure and the management interaction on the same day.

The announcement was made as a regulatory disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unaudited Q1 FY27 financials to be released before the call

Divi’s Laboratories stated that it will release its unaudited financial results for the quarter ended June 30, 2026 on the same day as the call. The company noted the results will be released prior to the investor discussion.

This sequencing typically allows market participants to review the reported numbers first and then use the call to focus on clarifications around revenue drivers, cost movement, and any segment-level performance commentary that management shares.

How investors can join: DiamondPass and dial-in

The company has provided two access routes for the conference call, including a registration-based option and a universal dial-in.

Investor Relations contact details

For follow-up questions, Divi’s Laboratories shared contact details for its Investor Relations department. Investors can reach out using the following:

• Mobile: +91 91542 18881
• Phone: +91 40 66966352
• Email: mail@divislabs.com

The company’s registered office address was also included in the disclosure: Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India.

Dividend record date fixed at July 24, 2026

Separately, Divi’s Laboratories has fixed July 24, 2026 as the record date to determine shareholder eligibility for a dividend of ₹30 per equity share for FY 2025-26.

The company stated that the dividend recommendation is subject to approval at the company’s 36th Annual General Meeting (AGM) scheduled for August 10, 2026. The disclosure also noted that the dividend of ₹30 per share on a face value of ₹2 translates to 1,500%.

When dividend payment is expected to start

If shareholders approve the payout at the AGM, the company said dividend payment will commence on or from August 14, 2026, subject to tax deduction at source (TDS).

What the company reported previously: Q1 FY26 snapshot

The provided context also includes details from a prior earnings call commentary for the quarter ended June 30, 2025. On a consolidated basis, Divi’s Laboratories reported total income of ₹2,529 crore for the quarter, compared with ₹2,197 crore in the corresponding quarter of the previous year.

For the same quarter, the company reported profit before tax (PBT) of ₹733 crore against ₹604 crore in the year-ago quarter, and profit after tax (PAT) of ₹545 crore against ₹430 crore in the corresponding period.

The company also stated that exports for the quarter were about 88%, and that its global nutraceutical business amounted to ₹250 crore for the quarter compared with ₹178 crore in the corresponding quarter of the previous year. It also cited constant currency growth of 14% for the quarter.

Quarterly results table shared in the data

A quarterly table in the provided text (figures in ₹ crore except per share values) lists the following metrics for the period labelled Jun 25, along with comparative figures.

FY26 audited numbers and dividend recommendation

The provided information also states that the board approved audited financial results for the year ended March 31, 2026. For FY26, Divi’s Laboratories reported revenue from operations of ₹10,894 crore and PAT of ₹2,607 crore.

The same context reiterates the final dividend of ₹30 per share recommended for FY26, subject to shareholder approval at the AGM, and confirms the record date of July 24, 2026.

Market datapoints mentioned in the provided text

The text includes select price and market data references. One section lists a current price of ₹6,754 with market capitalisation of ₹179,387 crore. Separately, a performance table in the provided content lists Divi’s Lab returns of 5.94% (1 day), 11.32% (1 week), 7.84% (1 month), -5.09% (3 month), 15.95% (6 month), and 5.60% (1 year).

These datapoints provide context for how investors may be positioning ahead of upcoming events such as quarterly disclosures and shareholder meetings.

Why the August 1 call matters for shareholders

The August 1, 2026 schedule sets up two near-term checkpoints for investors: the Q1 FY27 unaudited results release and the management interaction on the same day. In addition, the dividend timeline creates a separate sequence of key dates around the record date, AGM approval, and payment commencement window.

Together, these disclosures provide clarity on the company’s immediate calendar, including when financial information will be published, how to access the call, and how dividend eligibility and payout timing are structured.

Conclusion

Divi’s Laboratories will release unaudited Q1 FY27 results for the quarter ended June 30, 2026 and then hold an earnings call at 14:00 IST on August 01, 2026. Separately, shareholders are tracking the ₹30 per share FY26 dividend, with July 24, 2026 as the record date and the 36th AGM on August 10, 2026 for approval, followed by payment on or from August 14, 2026, if approved.